Device for guaranteed collection of first void urine

Colli-PeeTM (patent granted in Belgium & The Netherlands; CE-labelled) efficiently captures first-void urine (first part of the urine stream). Collection of first-void urine allows for detection of sexually transmitted infections (STIs), including Chlamydia, gonorrhea and Human Papilloma Virus (HPV), a virus which can cause cervical cancer, as well as cancer biomarkers. Colli-PeeTM is a user-friendly and compact device which is suited for postal delivery. It can be used by both men and women. The Colli-PeeTM device platform allows for collection of different pre-defined volumes for a range of medical applications.

Awards: IWT 'Innovation Award' in 2015 & 'Best of PO' in 2013 & 'Future-oriented product' at Design Week (Biennale INTERIEUR 2014)


First-void urine collection

Colli-Pee first-void FVU urine collection device body and colelctor tube by Novosanis

Usually first-void urine is collected by having the patient start to urinate into a specimen container, stop when the container is full, and then continue voiding into the toilet again. Colli-PeeTM is a device especially designed for first-void urine collection by capturing this first part of a urine sample more efficiently and requiring less effort from the user. Colli-PeeTM has a unique inherent float system, which prevents midstream urine from entering the specimen container after it has been filled with first-void urine, all the while creating a passage through which the superfluous urine can pass through the device into the toilet. With this device, the patient can collect a first-void urine sample without having to interrupt the urine stream. First-void urine can be used to detect e.g. Sexually Transmitted Infections.

Sexually Transmitted Infections

Colli-Pee first-void urine FVU collection device funnel view by Novosanis

First-void urine collection with Colli-PeeTM facilitates the detection of Sexually Transmitted Infections (STIs), including Chlamydia, gonorrhea and Human Papilloma Virus (HPV), of which the latter can cause cervical cancer. For the detection of STIs, a first-void urine sample needs to be collected, as this fraction of the urine stream contains more DNA and RNA particles than any other fraction and thereby improving the diagnostic result compared to midstream. The Colli-PeeTM device efficiently captures first-void urine and makes sure the superfluous urine is not collected, but flows into the toilet instead. Colli-PeeTM is a user-friendly device and provides an efficient, non-invasive sampling method.

Human Papilloma Virus (HPV)

Colli-Pee device for first-void FVU urine collection device ready for use by Novosanis

Human Papilloma Virus infection is a sexually transmitted infection (STI) that can be detected through the analysis of first-void urine. Colli-PeeTM collects first-void urine and enables detection of HPV. This infection is the most common STI: more than half of the people sexually active become infected at some point in their lives. HPV can cause many forms of cancer, including cervical cancer. Since HPV usually does not cause any symptoms, the virus can remain in the body unnoticed for years. Therefore, regular check-ups and/or screenings are important. Research is ongoing in which first-void urine using Colli-PeeTM is investigated as a non-invasive alternative method to detect HPV. UAntwerp and Novosanis are currently conducting a study on detection of HPV in urine and is still looking for volunteers.  

User instructions

  • Guaranteed first void
  • No need to interrupt urine current
  • Non-invasive self-sampling method
  • Suited for men and women
  • Shipment via regular mail
  • Respect dignity of patient
  • User-friendly
Clinical studies: 
BiR&D study (Belgium)

Aim: Performance of a new first-void collection device, Colli-PeeTM

  • Group A: 32 women, positive for HPV16 and/or 18 at earlier testing (HPV DNA on cervical samples).
  • Group B: 155 healthy volunteers (50 men, 105 women), HPV status unknown.
  • Detection of hDNA and HPV DNA in (first void) urine collected using Colli-Pee™ (Novosanis) and Multi-Collect™ (Abbott)

Conclusion: Urine collected using the Colli-PeeTM device yielded a higher number of copies of hDNA and HPV DNA compared to the Multi-Collect™ system.

WHO study (Rwanda & Bhutan)

Aim: Impact of HPV vaccination in Rwanda and Bhutan

  • 2500 girls aged 18 recruited in total
  • Detection of HPV using SPF10 primers and GP5+/6+ in first void urine collected with Colli-PeeTM device

Conclusion: analysis ongoing (preliminary data presented at EUROGIN 2015)

IWT study (Belgium)

Aim: Comparison HPV in urine collected using Colli-PeeTM device and regular urine collector

  • 50 HPV positive women to be included
  • Inclusion criterium: HPV positive at earlier testing  (HPV DNA on cervical samples)
  • Comparison yields hDNA and HPV DNA in first void urine collected in the morning and the evening

Conclusion: recruitment ongoing

EVAH study (Spain)

Aim: Use of self-sampling devices for detection of HPV

  • 100 women to be included
  • Comparison HPV detection on samples obtained from self-samples devices (EvalynTM brush and Colli-PeeTM) and clinician-based sampling
  • Comparison detection of HPV in first void urine collected in the morning and the evening
  • Inclusion criterium: HPV positive at earlier testing  (HPV DNA on cervical samples)

Conclusion: recruitment ongoing

SESAM study (Norway)

Aim: Use of self-sampling devices for detection of HPV

  • 300 women to be included
  • Comparison HPV detection on samples obtained from self-samples devices (EvalynTM brush, FLOQSwabsTM and Colli-PeeTM) and clinician-based sampling
  • Inclusion criterium: 250 CIN2+ patients and 50 cancer patients

Conclusion: recruitment ongoing

BD-Onclarity™ study (USA)

Aim: Performance of an automated HPV genotyping assay using first void urine
Partners: BD Diagnostics, University of Antwerp (VAXINFECTIO), Novosanis nv

  • Urine samples of 21 women
  • Comparison sample processing with the BD Viper LT automated assay and semi-automated reference method, samples from Colli-Pee™ compared to regular urine collector and comparison morning and evening urine.

Conclusion: The BD Viper LT automated assay proved a similar performance with a higher throughput and minimal hands on time, using a small sample volume and fully integrated workflow. Colli-Pee collection device resulted in a higher analytic sensitivity.
Publication: Poster IPV conference 2015: #P015.422

MaterialMedical grade polypropylene
Overall size210 x 105 x 46 mm
Overall size including transportation clip for postal delivery210 x 105 x 30 mm
Captured void20 ml
GenderMale & Female

Novosanis NV | +32 3 485 50 16 | welcome@novosanis.comBijkhoevelaan 32c, 2110 Wijnegem | Belgium